Literature DB >> 3904870

Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation.

J E Sokal, M Baccarani, S Tura, M Fiacchini, F Cervantes, C Rozman, G A Gomez, D A Galton, G P Canellos, T J Braun.   

Abstract

To obtain information relevant to the question of bone marrow transplantation, we examined the prognostic significance of disease features recorded at the time of diagnosis among 625 patients, aged 5 to 45, with Philadelphia chromosome-positive, nonblastic chronic granulocytic leukemia. The actuarial death rate for this population was 5% during the first year after diagnosis, 12% during the second year, and averaged 22.5% per year during the next eight years. Multivariable regression analysis of features recorded in nearly all cases indicated that sex, spleen size, hematocrit, platelet count, and percentage of circulating blasts were significant prognostic indicators. Analyses of additional data available in 113 to 421 cases suggested that serum lactic dehydrogenase activity, percentage of blasts in marrow, nucleated RBCs in blood, and percentage of basophils plus eosinophils might also provide useful prognostic information. A Cox model, generated with five variables representing features recorded regularly (the first five listed), permitted segregation of these patients into three groups with significantly different survival patterns. The high-risk group exhibited an actuarial mortality of 30% during the first two years after diagnosis and an annual risk of 30% thereafter. In contrast, the most favorable group had a two-year actuarial mortality of 9% and an average risk thereafter of 17% per year, with a median survival of 5 1/2 years. We conclude that it should be possible to classify potential candidates for bone marrow transplantation according to risk with conventional therapy. Such information may be useful in making decisions regarding early v deferred marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3904870

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.

Authors:  Nobuko Hijiya; Kirk R Schultz; Markus Metzler; Frederic Millot; Meinolf Suttorp
Journal:  Blood       Date:  2015-10-28       Impact factor: 22.113

Review 2.  Bone marrow transplantation. Part I--Allogeneic.

Authors:  N J Chao; K G Blume
Journal:  West J Med       Date:  1989-12

3.  Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.

Authors:  R Hehlmann; B Anger; D Messerer; R Zankovich; L Bergmann; H J Kolb; P Meyer; U Essers; U Queisser; H Vaupel
Journal:  Blut       Date:  1988-02

4.  Histological features of prognostic significance in CML--an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow.

Authors:  J Thiele; H M Kvasnicka; B R Titius; U Parpert; R Nebel; R Zankovich; D Dienemann; H Stein; V Diehl; R Fischer
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

5.  Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.

Authors:  Stéphane Flamant; William Ritchie; Joëlle Guilhot; Jeff Holst; Marie-Laure Bonnet; Jean-Claude Chomel; François Guilhot; Ali G Turhan; John E J Rasko
Journal:  Haematologica       Date:  2010-05-11       Impact factor: 9.941

6.  Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Treatment results of 69 patients.

Authors:  B Anger; F Carbonell; I Braunger; B Heinze; W Gutensohn; E Thiel; H Heimpel
Journal:  Blut       Date:  1988-09

7.  Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents.

Authors:  Frédéric Millot; Joëlle Guilhot; Meinolf Suttorp; Adalet Meral Güneş; Petr Sedlacek; Eveline De Bont; Chi Kong Li; Krzysztof Kalwak; Birgitte Lausen; Srdjana Culic; Michael Dworzak; Emilia Kaiserova; Barbara De Moerloose; Farah Roula; Andrea Biondi; André Baruchel
Journal:  Haematologica       Date:  2017-08-24       Impact factor: 9.941

8.  An approach to the management of chronic myeloid leukemia in British Columbia.

Authors:  D L Forrest; X Jiang; C J Eaves; C L Smith
Journal:  Curr Oncol       Date:  2008-04       Impact factor: 3.677

9.  Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century.

Authors:  Dianne Pulte; Benjamin Barnes; Lina Jansen; Nora Eisemann; Katharina Emrich; Adam Gondos; Stefan Hentschel; Bernd Holleczek; Klaus Kraywinkel; Hermann Brenner
Journal:  J Hematol Oncol       Date:  2013-09-16       Impact factor: 17.388

10.  The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: The Glivec International Patient Assistance Program (GIPAP).

Authors:  Chukwuemeka A Umeh; Pat Garcia-Gonzalez; David Tremblay; Richard Laing
Journal:  EClinicalMedicine       Date:  2020-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.